Bank of Montreal
KROS icon

Bank of Montreal’s Keros Therapeutics KROS Stock Holding History

Bank of Montreal’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-19,400
Closed -$933K – 3998
2022
Q4 		$933K Buy
+19,400
New +$906K ﹤0.01% 2222
2022
Q3 		– Sell
-11,613
Closed -$336 – 4255
2022
Q2 		$336 Buy
+11,613
New +$510K ﹤0.01% 2938
2021
Q2 		– Sell
-391
Closed -$25K – 4335
2021
Q1 		$25K Sell
391
-1,636
-81% -$104K ﹤0.01% 3972
2020
Q4 		$143K Buy
2,027
+1,705
+530% +$107K ﹤0.01% 3388
2020
Q3 		$12K Sell
322
-235
-42% -$9.32K ﹤0.01% 4059
2020
Q2 		$19K Buy
+557
New +$17.2K ﹤0.01% 3868

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Bank of Montreal's KROS Position: Q1 2023 in Review

Bank of Montreal sold out of Keros Therapeutics (KROS) in Q1 2023, closing a stake of 19,400 shares — an estimated $933K sold.

Bank of Montreal first reported a position in KROS in Q2 2020 and held it in 6 quarters. The position peaked at $933K in Q4 2022. 129 funds tracked by Wall St. Rank hold KROS as of Q1 2023.

  • Bank of Montreal reported no remaining Keros Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Bank of Montreal sold 19,400 Keros Therapeutics shares in Q1 2023, an estimated $933K.
  • Bank of Montreal first reported a position in Keros Therapeutics in Q2 2020 and held it in 6 quarters.
  • Bank of Montreal's Keros Therapeutics position peaked at $933K in Q4 2022.
  • 129 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2023.

Based on Bank of Montreal's 13F filing for Q1 2023, filed 13 Jun 2024.